Alnylam Pharmaceuticals, Inc.
ALNY
$332.92
$1.680.51%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -12.17% | 61.44% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -12.17% | 61.44% | |||
| Cost of Revenue | 33.76% | 40.01% | |||
| Gross Profit | -20.93% | 66.29% | |||
| SG&A Expenses | 1.02% | -0.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.56% | 11.54% | |||
| Operating Income | -64.21% | 2,371.63% | |||
| Income Before Tax | -32.57% | 775.86% | |||
| Income Tax Expenses | -108.68% | -139.18% | |||
| Earnings from Continuing Operations | -25.75% | 478.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -25.75% | 478.84% | |||
| EBIT | -64.21% | 2,371.63% | |||
| EBITDA | -61.96% | 17,030.60% | |||
| EPS Basic | -26.20% | 476.47% | |||
| Normalized Basic EPS | -56.40% | 912.78% | |||
| EPS Diluted | -25.67% | 462.63% | |||
| Normalized Diluted EPS | -55.79% | 877.87% | |||
| Average Basic Shares Outstanding | 0.60% | 0.63% | |||
| Average Diluted Shares Outstanding | -0.78% | 5.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||